Cirrhosis/Liver Failure News

BOSTON — Pegozafermin improved fibrosis and other key noninvasive tests at 24 weeks in patients with metabolic dysfunction-associated steatohepatitis-related cirrhosis, according to data presented at The Liver Meeting.

BOSTON — Female adolescents and young adults have higher rates of liver-related mortality and a 50% higher risk for cirrhosis and decompensation after surviving their first presentation of alcoholic hepatitis, according to data.

Topline findings from an extension of the phase 2b ENLIVEN trial showed that pegozafermin sustained improvements in fibrosis and disease resolution for patients with nonalcoholic steatohepatitis at 48 weeks, 89bio announced.

BOSTON — Oral naltrexone 50 mg safely improved alcohol use-related parameters and decompensation, and also reduced cravings, over 1 year among patients with alcohol use disorder and compensated cirrhosis, according to a presenter.

BOSTON — Treatment with TERN-501, a selective thyroid hormone receptor beta agonist, reduced liver fat content and fibro-inflammation among patients with presumed metabolic dysfunction-associated steatohepatitis, late-breaking data showed.

BOSTON — An educational program for transplant nurse coordinators did not improve advanced care planning among patients with decompensated cirrhosis, suggesting that provider training alone is “insufficient” to create significant change.

Patients with acute-on-chronic liver failure and recompensated cirrhosis had less severe disease, lower incidence of respiratory failure and better prognosis at 1 year vs. those with decompensated cirrhosis, researchers reported.

VANCOUVER, British Columbia — Substituting just one meat-based meal with protein from plant or dairy sources could improve metabolite signatures linked to hepatic encephalopathy in patients with cirrhosis, according to a presenter here.

VANCOUVER, British Columbia — Pain was reported in nearly 80% of patients with cirrhosis evaluated for liver transplant and, when paired with anxiety and depression, was a significant driver for poor quality of life, noted a presenter here.

Elevated serum triglyceride levels were associated with severity of acute pancreatitis and risk for related complications, including organ failure, among patients with nonalcoholic fatty liver disease, according to data.